drugset / Trial / NCT01738282

Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients

NCT01738282

Phase 3 Completed 316 enrolled Ethypharm
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to assess the efficacy of Xylka® (baclofen) compared to placebo on continuous abstinence rate during 20 weeks of treatment, after withdrawal, in alcohol dependent patients receiving Brenda therapy sessions.

Timeline

Start
2012-12
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Baclofen Small molecule 180 mg

Indications